Adenoviral Conjunctivitis follow-up timing: which statement is correct?

Prepare for the NBEO Part III Test with detailed quizzes on patient encounters and performance skills. Access flashcards and questions with explanations to enhance your study strategy. Perfect your skills for exam success!

Multiple Choice

Adenoviral Conjunctivitis follow-up timing: which statement is correct?

Explanation:
The key idea is how the use of a topical steroid changes how soon you recheck a patient with adenoviral conjunctivitis. Adenoviral conjunctivitis is typically self-limiting over a couple of weeks, so if you’re not using steroids, you follow the course and reassess after about 2–3 weeks to confirm resolution and watch for any complications. If a steroid is used, you need closer monitoring because steroids can alter healing, mask worsening disease, raise intraocular pressure, or promote steroid-related side effects. For this reason, the patient is rechecked much sooner—typically within 3–4 days—to ensure the infection is improving and to catch any adverse reactions early. The option reflecting this approach is the best, because it aligns follow-up timing with the safety considerations and healing trajectory when steroids are involved. The other timings—daily follow-up for a week, follow-up only at 1 month, or no follow-up at all—don’t fit the expected monitoring needs for this condition, especially when steroids are used.

The key idea is how the use of a topical steroid changes how soon you recheck a patient with adenoviral conjunctivitis. Adenoviral conjunctivitis is typically self-limiting over a couple of weeks, so if you’re not using steroids, you follow the course and reassess after about 2–3 weeks to confirm resolution and watch for any complications. If a steroid is used, you need closer monitoring because steroids can alter healing, mask worsening disease, raise intraocular pressure, or promote steroid-related side effects. For this reason, the patient is rechecked much sooner—typically within 3–4 days—to ensure the infection is improving and to catch any adverse reactions early. The option reflecting this approach is the best, because it aligns follow-up timing with the safety considerations and healing trajectory when steroids are involved. The other timings—daily follow-up for a week, follow-up only at 1 month, or no follow-up at all—don’t fit the expected monitoring needs for this condition, especially when steroids are used.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy